In the latest quarter, Q1'26, Pfizer's Gross Margin stands at 67.3%, reflecting a moderate decline from the previous quarter's 70.0%, while Operating Margin has improved significantly to 27.9% from a negative -9.4% in Q4'25, and Net Profit Margin remains stable at 18.6%, up slightly from -9.4% in the prior period. Over the period from Q2'23 to Q1'26, the chart reveals volatile trends across all margins, with Gross Margin fluctuating between a low of 30.0% in Q3'23 and a high of 79.3% in Q1'25, generally stabilizing above 67% in recent quarters after early declines. Operating and Net Profit Margins show pronounced swings, dipping into negative territory in Q3'23 (-25.3% and -18.0%, respectively) and Q4'23 (-28.9% and -23.6%), before recovering to positive levels in most subsequent quarters, with notable peaks in Q3'24 (26.6% and 25.2%) and Q1'26, indicating improved operational efficiency amid periodic challenges. Overall, the data suggests a trajectory toward greater stability and positivity in profitability metrics despite historical volatility.